OrbiMed Israel BioFund GP Limited Partnership 13D and 13G filings for 89bio, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-07-17 8:40 pm Purchase |
2024-07-15 | 13D | 89bio, Inc. ETNB |
OrbiMed Israel BioFund GP Limited Partnership | 17,877,653 9.990% |
5,299,832 (+42.14%) |
Filing |
| 2024-03-19 9:11 pm Purchase |
2024-03-15 | 13D | 89bio, Inc. ETNB |
OrbiMed Israel BioFund GP Limited Partnership | 12,577,821 19.900% |
7,976,013 (+173.32%) |
Filing |
| 2024-03-08 4:30 pm Purchase |
2024-03-06 | 13D | 89bio, Inc. ETNB |
OrbiMed Israel BioFund GP Limited Partnership | 4,601,808 9.900% |
48,319 (+1.06%) |
Filing |
| 2023-05-08 4:43 pm Purchase |
2023-05-04 | 13D | 89bio, Inc. ETNB |
OrbiMed Israel BioFund GP Limited Partnership | 4,553,489 9.900% |
1,017,000 (+28.76%) |
Filing |
| 2023-03-17 4:19 pm Purchase |
2023-02-27 | 13D | 89bio, Inc. ETNB |
OrbiMed Israel BioFund GP Limited Partnership | 3,536,489 10.500% |
3,536,489 (New Position) |
Filing |